Flok Health Raises $12.5 Million Series A to Scale the World's First Autonomous AI Physiotherapy Clinic Across the NHS

Flok Health, the Cambridge‑based medtech company behind Europe's first and only AI system cleared to autonomously diagnose, treat, and discharge patients without any clinician in the loop, has raised $12.5 million in an oversubscribed Series A to accelerate the national rollout of its AI physiotherapy clinic and expand into new clinical areas. The round was led by AlbionVC, with follow‑on participation from existing investors Eka VC and Form Ventures, and new strategic capital from Mercia Ventures.

The funding arrives at a critical inflection point for both the company and the NHS. What separates Flok from the broad field of healthcare chatbots is the regulatory standing behind it. The company is the first AI system in Europe to gain Class IIa medical device certification for the autonomous delivery of full care pathways, and the only digital musculoskeletal service approved by the UK's Care Quality Commission. Those dual regulatory credentials, uncommon in the extreme for any autonomous AI healthcare system, are the foundation on which Flok's commercial model is built.

The Problem It Was Built to Solve

Low back pain is the leading cause of disability globally and accounts for more than 30 million lost workdays annually in the UK. Meanwhile, more than 390,000 patients in England remain on waiting lists for MSK treatment. The structural challenge is not a shortage of clinical knowledge but a straightforward supply‑demand imbalance: there are significantly more patients requiring musculoskeletal care than there are physiotherapists available to treat them. The result is a system where patients routinely wait months for an initial appointment, during which their condition frequently worsens and their quality of life deteriorates.

Flok's response to this problem is architecturally unusual. Rather than an animated avatar, Flok manipulates real footage of a human physiotherapist to simulate a live video appointment that responds in real time to what a patient says and does. The intent is to preserve the texture of a clinician‑led session while the system underneath does the clinical reasoning. Patients access the service through a mobile app, receive a personalised assessment, and are guided through a treatment programme that includes exercise prescription, pain management techniques, and weekly progress monitoring, all without a human physiotherapist being involved at any stage of the pathway.

The system was built by Finn Stevenson, a former medic and rower who serves as CEO, and Ric da Silva, a software engineer. The two co‑founders met at CMR Surgical, the surgical robotics company, and brought a hardware and clinical engineering background to a software problem, which may partly explain the rigour with which they pursued regulatory approval before pursuing commercial scale.

What the NHS Data Shows

The evidence base for Flok's effectiveness draws on NHS operational data rather than controlled laboratory studies. The technology was deployed in Cambridgeshire and Peterborough in February 2025 by Cambridgeshire Community Services NHS Trust, the first NHS organisation in England to make Flok's AI clinic available to patients. During the 12‑week pilot, more than 2,500 people accessed the service, with overall MSK waiting times cut by 44 percent and back pain waiting lists reduced by 55 percent. The digital clinic saved hundreds of clinician hours each month and enabled most patients to be triaged, treated, and discharged through the digital pathway.

During a recent NHS rollout, more than 80 percent of patients reported that the AI clinic was as good as or better than seeing a human physiotherapist. That patient satisfaction metric matters enormously for a system that depends on NHS trust procurement and patient uptake. If patients actively preferred the human experience and used the AI pathway only as a fallback, the clinical case would be strong but the adoption case would be weak. An 80‑plus percent satisfaction benchmark suggests both are workable at scale.

In March 2026, the company's partnership with Cambridgeshire Community Services NHS Trust was named Health Service Journal's Primary and Community Care Project of the Year. That external validation from one of the UK's most authoritative healthcare management publications underlines the operational credibility of the deployment rather than just the product concept.

Where the $12.5 Million Goes

Flok Health will use the new funding to accelerate scaling its existing back pain service across the UK, while also expanding its clinical and geographical scope. The AI technology is currently being trained in other high‑volume care pathways including hip and knee pain and women's pelvic health conditions, with all three of these new services due to launch in the UK this year.

The clinical expansion into hip and knee pain is a logical adjacency. Both conditions share the same MSK care pathway infrastructure as back pain, sit on the same NHS waiting lists, and affect millions of patients annually. Women's pelvic health is a more distinct expansion but one that reflects Flok's ambition to demonstrate that the autonomous care model is pathway‑agnostic rather than specific to musculoskeletal conditions.

The company is also targeting international markets, with the funding earmarked for initial geographic expansion beyond the UK. Autonomous AI‑delivered healthcare faces different regulatory environments in each market, but the Class IIa certification and CQC approval provide a credentialed starting point for regulatory conversations with international health authorities.

Finn Stevenson described AI as a generational opportunity to close the supply‑demand gap in healthcare and ensure that anyone, anywhere, can access the best possible care whenever they need it. With 2.4 million potential NHS patients now within reach of the platform and a clinical pipeline expanding beyond back pain, Flok enters the second half of 2026 as one of the more credibly positioned autonomous health AI companies anywhere in the world.